

140. Haddad J, Latoche JD, Nigam S, Bellavia MC, Day KE, Zhu Q, Edwards WB, **Anderson CJ**, Tavakoli S. Molecular imaging of very late antigen-4 (VLA-4) in acute lung injury. *Journal of Nuclear Medicine*, 2021; 62:280-286.
141. Dai L, Zhang J, Wong CT, Chan WTK, Ling X, **Anderson CJ**, Law G-L. Design of Functional Chiral Cyclen-based Radiometal Chelators for Theranostics. *Inorganic Chemistry* 2021; 60:7082-7088.
142. Mattila J, Beaino W, White AG, Nyiranshuti L, Maello PA, Tomko J, Frye J, Fillmore D, Scanga CA, Lin, PL, Flynn JL, **Anderson CJ**. Retention of (64)Cu-FLFLF, a Formyl Peptide Receptor 1-Specific PET Probe, Correlates with Macrophage and Neutrophil Abundance in Lung Granulomas from Cynomolgus Macaques. *ACS Infectious Disease*; 2021; 7:2264-2276; DOI: 10.1021/acinfeddis.0c00826.
143. Foster A, Nigam S, Tatum DS, Raphael I, Xu J, Kumar R, Plakseychuk E, Latoche JD, Vincze S, Li B, Giri R, McCarl LH, Edinger R, Ak M, Peddagangireddy V, Foley LM, Hitchens TK, Colen RR, Pollack IF, Panigrahy A, Magda D*, **Anderson CJ***, Edwards WB*, Kohanbash G*. Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumor-infiltrating immune cells in glioma. *EBioMedicine*, 2021; 17:103571. (*co-corresponding authors)
144. Bellavia MC, Nyiranshuti L, Latoche JD, Ho K-V, Fecek RJ, Taylor JL, Day KE, Nigam S, Pun M, Gallazzi F, Edinger RS, Storkus WJ, Patel RB*, **Anderson CJ***. PET imaging of VLA-4 in a new BRAF^{V600E} mouse model of melanoma. *Molecular Imaging and Biology*; 2022; 24:425-433; DOI 10.1007/s11307-021-01666-1. (*co-corresponding authors)
145. Mandell JB, Douglas N, Ukani V, Beumer JH, Guo J, Payne J, Newman R, Mancinelli L, Intini G, **Anderson CJ**, Watters R, Weiss K. *ALDH1A1* gene expression and cellular copper levels between low and highly metastatic osteosarcoma provide a case for novel repurposing with disulfiram and copper. *Sarcoma*, 2022; 2022:7157507.
146. Kankanamalage PHA, Hoerres R, Ho K-V, **Anderson CJ**, Gallazzi F, Hennkens HM. *p*-NCS-Bn-NODAGA as a bifunctional chelator for radiolabeling with the ¹⁸⁶Re/^{99m}Tc-tricarbonyl core: Radiochemistry with model complexes and a GRPR-targeting peptide. *Nuclear Medicine and Biology*, 2022; 108-109:1-9.
147. Olatunji FP, Pun M, Herman JW, Romero O, Maniatopoulos M, Latoche JD, Parise RA, Guo J, Beumer JH, **Anderson CJ***, Berkman CE*. Modular Smart Molecules for PSMA-Targeted Chemotherapy. *Molecular Cancer Therapeutics*, Published on-line August 23, 2022; <https://doi.org/10.1158/1535-7163.MCT-22-0160>.
147. Mannes PZ, Barnes CE, Biermann J, Latoche JD, Day KE, Zhu Q, Tabary M, Xiong Z, Nedrow JR, Izar B, **Anderson CJ**, Villanueva FS, Lee JS, Tavakoli S. Molecular imaging of chemokine-like receptor 1 (CMKLR1) in experimental acute lung injury. *Proceedings of the National Academy of Sciences* 2023; 120 (3) e2216458120. <https://doi.org/10.1073/pnas.2216458120>
148. Zhu Q, Barnes CE, Mannes PZ, Latoche JD, Day KE, Nedrow JR, Novelli EM, **Anderson CJ**, Tavakoli S. Targeted Imaging of Very Late Antigen-4 for Noninvasive Assessment of Lung Inflammation-Fibrosis Axis. *European Journal of Nuclear Medicine and Molecular Imaging Research*, 2023; 13:55. <https://doi.org/10.1186/s13550-023-01006-0>
149. Nisnboym M, Vincze SR, Xiong Z, Sneiderman CT, Raphael RA, Sever RE, Li B, Jaswal AP, Day KE, Latoche JD, Foley LM, Karimi H, Hitchens KT, Agnihotri S, Hu B, Rajasunderam D, **Anderson CJ**, Blumenthal DT, Pearce TM, Uttam S, Nedrow JR, Panigrahy A, Pollack IF, Lieberman FS, Drappatz J, Raphael I*, Edwards WB*, Kohanbash G*. Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival following Immunotherapy in Murine GBM. *Cancer Research Communications* 2023; 3:1173-1188; <https://doi.org/10.1158/2767-9764.CRC-22-0434>.

150. Pun MD, Gallazzi F, Ho K-V, Watkinson L, Carmack TL, Iweha E, Li L, **Anderson CJ***. Albumin-binding Lutetium-177 LLP2A Derivatives as Theranostics for Melanoma. *Molecular Pharmaceutics* 2024; 21:2960-2969. <https://doi.org/10.1021/acs.molpharmaceut.4c00095>.
151. Rachedi NS, Tang Y, Tai Y-Y, Zhao J, Chauvet C, Grynblat J, Akoumia KKF, Estephan L, Torrino S, Sbai C, Ait-Mouffok A, Latoche JD, Al Aaraj Y, Brau F, Abelanet S, Clavel, Zhang Y, Guillermier C, Kumar NVG, Tavakoli S, Mercier O, Risbano MG, Yao Z-K, Yang G, Ouerfelli O, Lewis JS, Montani D, Humbert M, Steinhauser ML, **Anderson CJ**, Oldham WS, Peros F, Bertero T, Chan SY. Dietary intake and glutamine-serine metabolism control pathological vascular stiffness. *Cell Metabolism* 2024; 36:1335-1350 e8. <https://doi.org/10.1016/j.cmet.2024.04.010>
152. Lewis MR, Schaedler AW, Ho K-V, Golzy M, Mathur A, Pun M, Gallazzi F, Watkinson LD, Carmack TL, **Anderson CJ**, Smith CJ. Evaluation of a bimodal, matched pair theranostic agent targeting prostate-specific membrane antigen. *Nuclear Medicine and Biology*, 2024; 136-137: 108938. <https://doi.org/10.1016/j.nucmedbio.2024.108938>
153. Ho K-V, Tatum DS, Watkinson L, Carmack TL, Jia F, Mascioni A, Maitz CA, Magda DM, **Anderson CJ***. Single chelator-minibody theranostic agents for Zr-89 PET imaging and Lu-177 radiopharmaceutical therapy of PSMA-expressing prostate cancer. *Journal of Nuclear Medicine*, 2024; 65:1435-1442, DOI: <https://doi.org/10.2967/jnumed.124.267667>
154. Reyes-Gonzalez JM, Rajkumar H, Lee W, Baidoo K, Edinger R, Diehl G, Nambiar D, Okada R, Edmonson E, Fayn S, Buckley J, Jaswal AP, Cortez AG, Marsh I, Josefsson A, Kohanbash G, Nedrow JR, **Anderson CJ**, Escorcía FE, Nguyen R, Patel RB. Evaluation of VLA-4 (integrin $\alpha 4\beta 1$) as a shared target for radiopharmaceutical therapy across solid tumors. *Molecular Cancer Therapeutics*, 2025; 24:896-906; <https://doi.org/10.1158/1535-7163.MCT-24-0370>
155. Bokolo P, Serashinghe M, Kuchuk M, Guthrie J, Embree M, Wilder S, Medvedev DG, Cutler CS, Wilbur DS, Li Y, **Anderson CJ**, Jurisson SS, Hennkens HM. Production and Purification of Research Scale ^{161}Tb Using Cation-Exchange Semi-Preparative HPLC for Radiopharmaceutical Applications. *Radiochimica Acta*, 2025; 113: 445-467; <https://doi.org/10.1515/ract-2024-0363>
156. Li L, Wirrick A, Pun MD, Lovingier CL, Gallazzi F, Watkinson L, Carmack TL, Rodgers M, Tucker K, Ho K-V, **Anderson CJ**. Effect of click chemistry linkages on biological behavior of albumin-binding ^{177}Lu -DOTAGA-pIBA-LLP2A analogues. *Bioconjugate Chemistry*, 2025; 36: 2002-2012; <https://doi.org/10.1021/acs.bioconjchem.5c00277>
157. Fong COY[#], Iweha EV[#], Gallazzi F, Mathur A, Heyne O, Mootz J, Mayher, Tatum DS, Magda D, **Anderson CJ**. Matched pair suitability of ^{89}Zr and ^{177}Lu -labeled L804-LLP2A theranostics for targeting VLA-4 in melanoma ([#]authors contributed equally); *Nuclear Medicine and Biology* 2026; 152-153: 109597. <https://doi.org/10.1016/j.nucmedbio.2025.109597>
158. Ocak EM, Sikligar K, Pun M, Ho K-V, Ling X, Carroll VN, Simón J, Fulton MD, Bombá HN, Berkman CE, Langton-Webster BC, **Anderson CJ**. Development of a one-step radiolabeling procedure for a PSMA-targeted radiotherapeutic for prostate cancer. *Nuclear Medicine and Biology*, 2026; 154-155:109607.
159. Li B, Vincze S, Jaswal AP, Sneiderman C, Birikorang P, Menendez D, Edinger R, Pun M, Laymon CM, **Anderson CJ***, Kohanbash G*, Edwards WB*. [^{64}Cu]Cu-labeled aCD11b diabody as a novel PET tracer for early detection of immunosuppression in glioblastoma; *ACS Omega* 2026; 11:13835-13844. *co-senior authors
160. Yadav N, Zhu Q, Little-Ihrig LL, Latoche JD, Day KE, Sikligar K, Tavakoli S, Novelli EM, **Anderson CJ**. Hydroxyurea reduces hyper-adhesion measured by a VLA-4 targeting PET tracer in sickle transgenic Townes mice. On-line first 2026: <https://doi.org/10.1182/bloodadvances.2025019423>

161. Rodriguez C, Edinger R, Reyes-González JM, Diehl G, Lee W, Buckley J, Oh J, Nambiar D, Baidoo K, Okada R, Sakhalkar Y, Cortez AG, Josefsson A, Nedrow JR, Zhang X, **Anderson CJ**, Escorcia FE, Patel RB, Nguyen R. Radiopharmaceutical therapy enhances CAR T-cell activity against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and tumor microenvironment remodeling, in revision.